Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Innate and adaptive immunity affect the pathogenesis of Parkinson's disease (PD). In particular, activation of microglia influences degeneration of dopaminergic neurons. Cell-to-cell interactions and immune regulation critical for neuronal homeostasis also influence immune responses. The links between T cell immunity and nigrostriatal degeneration are supported by laboratory, animal model, and human pathologic investigations. Immune-associated biomarkers in spinal fluids and brain tissue of patients with idiopathic or familial forms of PD provide means to improve diagnosis and therapeutic monitoring. Relationships between oxidative stress, inflammation, and immune-mediated cell death pathways are examined in this review as they are linked to PD pathogenesis. Harnessing the immune system by drugs or by vaccination remain promising future therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · cited 2×
“Microglia actively monitor the CNS environment by continual movement of their fine processes in the healthy brain (106), key in immune surveillance functions.”
BackgroundSakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 4×
“Detection of disturbances within the neuron microenvironment induces microglia to become activated and affect a graded response (84).”
BackgroundInfluentialProtein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“Indeed, misfolded proteins are found in inclusion bodies associated with several neurodegenerative diseases (40, 63, 74, 121).”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 2×
“Furthermore, dendritic cell function can be conditioned to express indoleamine 2,3-dioxygenase (IDO) through interactions between CTLA4 and CD80 and CD86, resulting in suppression of effector T cells (147, 158).”
BackgroundPPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 2×
“Furthermore, dendritic cell function can be conditioned to express indoleamine 2,3-dioxygenase (IDO) through interactions between CTLA4 and CD80 and CD86, resulting in suppression of effector T cells (147, 158).”
Background
Cited by
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
“In PD brain the BBB (blood brain barrier) is disrupted due to activated microglia and monocytes (Stone et al., 2009) and IgG, has been shown bound to dopamine neurons in the substantia nigra of idiopathic and familial PD patients, but not in age-matched controls (Orr et al., 2005).”
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Zhou, Y., Lu, M., Du, R.-H., Qiao, C., Jiang, C.-Y., Zhang, K.-Z., Ding, J.-H., & Hu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0094-3 · Cited by 455
Genome-wide pleiotropy between Parkinson disease and autoimmune diseases
Witoelar, A., Jansen, I. E., Wang, Y., Desikan, R. S., Gibbs, J. R., Blauwendraat, C., Thompson, W. K., Hernandez, D. G., Djurovic, S., Schork, A. J., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0469 · Cited by 352
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy
Qian, L., Flood, P. M., & Hong, J.-S. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0428-1 · Cited by 287
CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease
Galiano-Landeira, J., Torra, A., Vila, M., & Bové, J. (2020) · Brain · doi:10.1093/brain/awaa269 · Cited by 267
Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson’s Disease
More, S. V., Kumar, H., Kim, I. S., Song, S.-Y., & Choi, D.-K. (2013) · Mediators of Inflammation · doi:10.1155/2013/952375 · Cited by 258
Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair
Vivekanantham, S., Shah, S., Dewji, R., Dewji, A., Khatri, C., & Ologunde, R. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.982795 · Cited by 171
“It has been proposed that they suppress immune activity and microglial function through multiple mechanisms including: release of IL-10 and TGFB1, suppression of metabolic functions in effector cells and induction of apoptotic tolerance [38, 39].”
BackgroundCrowley, T., Cryan, J. F., Downer, E. J., & O’Leary, O. F. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.02.001 · Cited by 150
Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“Other strategies interfering with the infiltration of peripheral CD4+/CD8+ T lymphocytes, which was reported as a contributing factor of DA neurodegeneration (Brochard et al. 2009; Appel 2009; Stone et al. 2009), also revealed neuroprotection.”
BackgroundImaging of microglia in patients with neurodegenerative disorders
Politis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00096 · Cited by 111
Blau, C. W., Cowley, T. R., O'Sullivan, J., Grehan, B., Browne, T. C., Kelly, L., Birch, A., Murphy, N., Kelly, A. M., Kerskens, C. M., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.035 · Cited by 92
Macrophages Offer A Paradigm Switch for CNS Delivery of Therapeutic Proteins
Klyachko, N. L., Haney, M. J., Zhao, Y., Manickam, D. S., Mahajan, V., Suresh, P., Hingtgen, S. D., Mosley, R. L., Gendelman, H. E., Kabanov, A. V., et al. (2014) · Nanomedicine · doi:10.2217/nnm.13.115 · Cited by 92
Self-citationYao, R., Pan, R., Shang, C., Li, X., Cheng, J., Xu, J., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00986 · Cited by 79
Diabetes type II: A risk factor for depression-Parkinson–Alzheimer?
Riederer, P., Bartl, J., Laux, G., & Grünblatt, E. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9203-1 · Cited by 51
“An infection or immune process, possibly itself associated with stress (Stone et al. 2009), could activate the HPA axis (Kyrou and Tsigos 2009).”
BackgroundAspects of innate immunity and Parkinson's disease
Huang, Y., & Halliday, G. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00033 · Cited by 22
Metadata
- Authors
- Stone, D. K., Reynolds, A. D., Mosley, R. L., & Gendelman, H. E.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2009-09
- Volume
- 11
- Issue
- 9
- Pages
- 2151-2166
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2038726784
- Cited by
- 132
- References
- 25
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.